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Background—Interindividual variability of platelet inhibition after aspirin or clopidogrel administration has been
described. Additionally, aspirin resistance and clopidogrel resistance occur in some individuals. Because the prodrug
clopidogrel is activated by hepatic cytochrome P450 (CYP) 3A4, we hypothesized that interindividual variability in
clopidogrel efficacy might be related to interindividual differences in CYP3A4 metabolic activity.
Methods and Results—Platelet aggregation was measured before and after clopidogrel treatment in 32 patients undergoing
coronary artery stent implantation and in 35 healthy volunteers. The erythromycin breath test was used to measure
CYP3A4 activity in vivo in 25 of the healthy volunteers. Individual platelet aggregation was studied in 10 healthy
volunteers after the coadministration of clopidogrel and rifampin (a CYP3A4 inducer). Clopidogrel nonresponders, low
responders, and responders were defined by a relative inhibition of adenosine diphosphate (20 mol/L)–induced platelet
aggregation of 10%, 10% to 29%, and 30%, respectively. Among patients, 22% were clopidogrel nonresponders,
32% were low responders, and 47% were responders. Among volunteers, 16% were nonresponders, 12% were low
responders, and 72% were responders. Percent platelet aggregation after clopidogrel inversely correlated with CYP3A4
activity (r0.6, P0.003). Improved platelet inhibition in volunteers resistant to clopidogrel was observed with the
coadministration of clopidogrel and rifampin.
Conclusions—Clopidogrel administration results in interindividual variability in platelet inhibition, which correlates with
CYP3A4 metabolic activity. Measurement of antiplatelet drug efficacy with a point-of-care device and alternative
antithrombotic strategies for aspirin or clopidogrel nonresponders and low responders could reduce the incidence of
thrombotic events that continue to occur despite oral antiplatelet therapy. (Circulation. 2004;109:166-171.)
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Clopidogrel, a thienopyridine derivative similar to ticlo-pidine, is an inhibitor of platelet aggregation induced by
adenosine diphosphate (ADP).1 Clopidogrel was approved by
the United States Food and Drug Administration (FDA) in
1997 for the reduction of myocardial infarction, stroke, and
vascular death in patients with recent stroke, recent myocar-
dial infarction, or established peripheral arterial disease after
the Clopidogrel versus Aspirin in Patients at Risk of Ischemic
Events (CAPRIE) trial2 showed superior reduction of these
events with clopidogrel compared with aspirin (annual risk,
5.3% versus 5.8%; P0.04). Dual antiplatelet therapy (aspi-
rin plus clopidogrel) for acute coronary syndromes was
approved by the FDA in 2002 on the basis of the Clopidogrel
in Unstable angina to prevent Recurrent ischemic Events
(CURE) trial3 results, which showed a significant reduction in
the 9-month composite end point of cardiovascular death,
nonfatal myocardial infarction, or stroke versus aspirin mono-
therapy (9.3% versus 11.4%, P0.001). Additionally, the
combination of aspirin and clopidogrel is the standard anti-
platelet therapy for coronary stenting,4–7 although it has not
gained formal FDA approval status.
The elucidation of the pharmacological properties of clo-
pidogrel has lagged behind the randomized clinical trial
reports. A 75-mg once-daily clopidogrel dose was used in
CAPRIE because it produced inhibition of ADP-induced
platelet aggregation equivalent to ticlopidine 250 mg twice
daily.2 Only later were dosing studies published,8,9 and this
work continues.10–11 Subsequently, the active metabolite of
clopidogrel, a prodrug, was identified,12 and its noncompet-
itive inhibition of the platelet P2 Y12 ADP receptor was
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described.13 We recently demonstrated that clopidogrel is
activated in humans by the hepatic cytochrome P450 (CYP)
3A4 enzyme system and that its platelet inhibition efficacy
could be perturbed by CYP3A4 inhibitors, inducers, and
substrates.14,15
Interindividual variation in platelet inhibition by clopi-
dogrel has long been recognized but only recently evaluated
in peer-reviewed manuscripts.16–18 Clopidogrel resistance, a
concept related to aspirin resistance,19–22 has also been
described.18,23,24 This phenomenon includes both clopidogrel
nonresponders and low responders.24 Possible mechanistic
explanations include increased platelet reactivity before clo-
pidogrel dosing,17,18 drug–drug interactions inhibiting clopi-
dogrel activation by CYP3A4,14,15 platelet P2 Y12 receptor
genetic polymorphisms,25 or defects in signaling pathways
downstream from the receptor. In the present study, we
demonstrate that low baseline CYP3A4 activity, which de-
creases clopidogrel activation, is one mechanism for clopi-
dogrel resistance, at least during the first days of treatment.
Methods
Study Protocols
The institutional review boards approved the protocols, and written
informed consent was obtained from each subject before enrollment.
In the first study, 32 consecutive patients undergoing elective
coronary artery stent implantation received an oral loading dose of
300 mg of clopidogrel followed by 75 mg daily.18 Exclusion criteria
included history of bleeding diathesis, acute myocardial infarction
within 48 hours, cerebrovascular event within 3 months, illicit drug
or alcohol abuse, prothrombin time 1.5 times control, platelet
count 100 000/mm3, hematocrit 25%, creatinine 4.0 mg/dL,
and thienopyridine or glycoprotein IIb/IIIa use before the procedure.
All patients received at least 81 mg aspirin for 7 days before the
procedure and were administered 325 mg on the day of the procedure
and daily thereafter. Heparin was administered in the catheterization
laboratory to all patients to achieve an activated clotting time 300
seconds. Glycoprotein IIb/IIIa inhibitors were withheld. Blood was
collected in Vacutainer tubes (Becton Dickinson) containing 3.8%
trisodium citrate. Samples were obtained at baseline before clopi-
dogrel or heparin therapy and at 5 days after stent implantation.
Platelet aggregation was measured by light transmission
aggregometry.
In the second study, the metabolic activity of CYP3A4 was
compared with platelet aggregation after a 450-mg loading dose of
clopidogrel in 25 healthy volunteers. Exclusion criteria included
history of platelet count 100 000/mm3, bleeding disorder, or
ingestion of any medications, alcohol, caffeine, tobacco, herbal
remedies such as St John’s wort, grapefruit juice, birth control pills,
or charcoal-broiled food. An erythromycin breath test was performed
before and 2 hours after ingesting clopidogrel to measure CYP3A4
activity.26 Platelet aggregation was measured before and 4 hours
after clopidogrel ingestion using a point-of-care aggregometer.
The third study analyzed individual platelet aggregation inhibition
in 10 healthy volunteers who received a maintenance dose of
clopidogrel 75 mg/d for 6 days, followed by a washout period of 14
days, followed by 4 days of rifampin 300 mg twice a day, followed
by 6 days of both clopidogrel and rifampin.14 Exclusion criteria were
the same as in the second study. Platelet aggregation was determined
with the point-of-care aggregometer on days 0, 6, 20, 24, and 30.
Platelet Aggregation
Platelet aggregation was measured in the first study using platelet-
rich plasma stimulated with 20 mol/L ADP and assessed with a
Chronolog Lumi-Aggregometer (model 560-Ca, Chronolog) with the
AggroLink software package.27 After inverting the Vacutainer tube 3
to 5 times for gentle mixing, the blood-citrate mixture was centri-
fuged at 1200g for 2.5 minutes. The resulting platelet-rich plasma
was kept at room temperature for use within 1 hour. The platelet
count was determined in the platelet-rich plasma and adjusted to
3.5108/mL with homologous platelet-poor plasma. Aggregation
was expressed as the maximal percent change in light transmittance
from baseline, using platelet-poor plasma as a reference. Inhibition
of platelet aggregation was expressed as the absolute reduction in
aggregation achieved by 20 mol/L ADP after clopidogrel admin-
istration compared with baseline aggregation values before clopi-
dogrel. Nonresponders were defined by a platelet inhibition of
10%, low responders were characterized by inhibition of platelet
aggregation by 10% to 29%, and normal responders were 30%
responsive.24
Platelet aggregation for the second and third studies was measured
with the point-of-care MICROS cell counter (ABX Diagnostics) and
the Plateletworks test platform (Helena Laboratories). The cell
counter uses traditional electronic impedance cell counting princi-
ples.28,29 In brief, a reference platelet count is performed on 1 mL of
fresh whole blood in a Plateletworks tube containing K3-EDTA as
the anticoagulant. The sample is then passed through the cell counter
and the platelet count is determined. This process is repeated with a
second 1-mL sample of fresh whole blood in a Plateletworks tube
containing both citrate and 20 mol/L ADP. In the presence of ADP,
platelets associate and aggregate. Because the aggregated platelets
exceed the threshold limitations for platelet size, they are no longer
counted as individual platelets. The ratio of the platelet count
between the agonist and reference tubes is calculated as percent
platelet aggregation. The results are available within 4 minutes. A
previous study comparing this device to light transmission aggre-
gometry using platelet-rich plasma demonstrated a correlation coef-
ficient of 0.83 in 225 paired samples.29
Erythromycin Breath Test
The erythromycin breath test (Metabolic Solutions, Inc) was used to
measure hepatic CYP3A4 activity in vivo in the second study.26 A
preinjection breath sample was obtained. An intravenous dose of
[14C-N-methyl]-erythromycin (3 Ci, 0.01 mmol of erythromycin)
was then administered. Subsequently, a single breath sample was
collected after 20 minutes. Quantitation of exhaled 14CO2 provides a
selective measure of the instantaneous hepatic CYP3A4 activity.30
Statistics
In patients undergoing stent implantation, paired 2-sample t tests
were used to compare platelet aggregation between 0 and 5 days.
Linear regression plot comparing the baseline CYP3A4 metabolic
activity and postclopidogrel CYP3A4 activity with percent platelet
aggregation before and after clopidogrel was performed using SPSS
statistical analysis. In healthy volunteers taking rifampin, paired
2-sample t tests with Bonferroni’s correction were used to compare
platelet aggregation between 0, 6, 20, 24, and 30 days within each
group. Nonparametric data that did not conform to a normal
distribution were analyzed using Mann-Whitney U tests for unpaired
data and Wilcoxon tests for paired data. All values were expressed as
meanSD. P0.05 was considered statistically significant.
Results
Variable Clopidogrel Response
Interindividual variability in platelet inhibition was demon-
strated in both patients and healthy volunteers. In patients, 7
of 32 (22%) were clopidogrel nonresponders, 10 of 32 (32%)
were low responders, and 15 of 32 (47%) were responders
(Figure 1). In healthy volunteers, 4 of 25 (16%) were
clopidogrel nonresponders, 3 of 25 (12%) were low respond-
ers, and 18 of 25 (72%) were responders (Figure 2).
Clopidogrel Response Versus CYP3A4 Activity
Baseline CYP3A4 activity was randomly distributed, as
measured by the erythromycin breath test, and was not related
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to baseline percent platelet aggregation in 25 healthy volun-
teers (Figure 3A). After clopidogrel (Figure 3B), there was a
significant inverse correlation between platelet aggregation
and CYP3A4 activity (r0.6; P0.003).
CYP3A4 Induction
Clopidogrel produced interindividual variability in platelet
aggregation inhibition in 10 healthy volunteers (Figure 4).
Rifampin did not change platelet aggregation, but platelet
aggregation inhibition after clopidogrel was enhanced by
rifampin (5620% versus 3318%; P0.001), a CYP3A4
inducer. After rifampin, the 3 initial nonresponders and 1 low
responder demonstrated enhanced platelet inhibition that then
met the definition for a clopidogrel responder (Figure 4).
Discussion
The variable platelet inhibition response to clopidogrel has
been recognized by all who have tested clopidogrel efficacy
by platelet aggregometry, and clopidogrel resistance has
recently been described.18,23,24 In a previous report, the
incidence of clopidogrel nonresponders was 10% and the
incidence of low responders was 20%.24 These frequencies
are similar to those reported for aspirin resistance using
platelet aggregometry.19 Others have demonstrated higher
frequencies for clopidogrel resistance, reporting an absolute,
rather than a relative, change in platelet aggregation.18 This is
an important differentiation, because it may be argued that
aspirin might influence the prevalence of clopidogrel nonre-
sponders. However, because the response to clopidogrel in
this study was reported as a relative change in platelet
aggregation, any change can be attributed to clopidogrel
administration alone. We previously demonstrated that
clopidogrel, a prodrug, was activated in humans by
CYP3A4.14,15 In the present study, we offer additional evi-
dence in support of that observation and describe 1 mecha-
nism to explain clopidogrel resistance: individual variability
in the metabolic activity of CYP3A4.
In our earlier study,14 we showed that the pharmacological
manipulation of CYP3A4 metabolic activity affected the
ability of clopidogrel to inhibit platelet aggregation, as
measured by platelet aggregometry. Erythromycin and trole-
andomycin, CYP3A4 inhibitors, decreased clopidogrel effi-
cacy, as did atorvastatin lactone, a competitive CYP3A4
substrate. In contrast, rifampin, a CYP3A4 inducer, increased
clopidogrel efficacy.
There exists substantial interindividual variation in
CYP3A4 expression that cannot be accounted for by known
inducers and inhibitors.31 A genetic basis for this variation
has not been identified, but it is possible to use the erythro-
mycin breath test to determine an individual’s CYP3A4
activity. In our second study performed in healthy volunteers,
the baseline distribution of individual CYP3A4 metabolic
activity was randomly distributed (Figure 3A). CYP3A4
activity levels correlated with platelet aggregation values
Figure 1. Percent platelet aggregation induced by 20 mol/L
ADP at baseline and 5 days after initiating clopidogrel therapy in
32 patients undergoing coronary stent implantation.
Figure 2. Percent platelet aggregation induced by 20 mol/L
ADP at baseline and 4 hours after initiating clopidogrel therapy
in 25 healthy volunteers.
Figure 3. Percent platelet aggregation compared with CYP 3A4
activity, as measured by the erythromycin breath test before (A)
and after (B) clopidogrel loading.
168 Circulation January 20, 2004







after clopidogrel, and the correlation was inverse, as expected
(ie, the lower the CYP3A4 activity, the less clopidogrel was
activated [Figure 3B]). Variation in hepatic CYP3A4 activity
accounted for approximately one third (R0.36) of the
interindividual variability in response. In a patient population
receiving potential inducers and inhibitors of CYP3A4 and
who may have varying degrees of liver dysfunction because
of disease, variation in CYP3A4 activity would be signifi-
cantly greater than in our healthy volunteers. A logical
hypothesis is that variation in CYP3A4 activity would ac-
count for significantly more than one third of the variability
in clopidogrel response in patients.
Our data also show that the role of CYP3A4 in clopidogrel
activation can be exploited to convert nonresponders. In
Figure 4, it can be seen that clopidogrel efficacy in 3
nonresponders and 1 low responder was improved by coad-
ministration of rifampin. This suggests that agents that induce
the expression of CYP3A4 metabolic activity can decrease
the incidence of clopidogrel resistance.
The different definitions of antiplatelet drug resistance are
empiric. Muller et al24 defined clopidogrel nonresponse as a
relative inhibition of ADP-induced platelet aggregation of
10%. Low responders were identified by an inhibition of
10% to 29%. Whereas platelet receptor P2 Y12 genetic
polymorphisms25 or defects in signaling pathways down-
stream from the receptor would represent durable mecha-
nisms for clopidogrel resistance, the observation that some
patients with initial clopidogrel resistance become more
responsive to clopidogrel over time23 could be explained
either by subsequent induction of CYP3A4 expression and
increased metabolism of the prodrug or decreasing platelet
reactivity after stenting. Increased loading (300 mg) or
maintenance (75 mg) doses would be expected to decrease
clopidogrel resistance because of baseline platelet activa-
tion.17,18 The Intracoronary Stenting and Antithrombotic Reg-
imen–Rapid Early Action for Coronary Treatment (ISAR-
REACT) study7 demonstrated no difference between
glycoprotein IIb/IIIa receptor inhibitors and placebo in low-
risk patients undergoing coronary stent implantation treated
with a 600-mg loading dose of clopidogrel.
Aspirin resistance has been defined either as the failure
to prevent individuals from clinical thrombotic complica-
tions or as the failure to produce an expected response on
a laboratory measurement of platelet activation or aggre-
gation.22 Unfortunately, the incidence varies from 5% to
50%, depending on the definition used, the test used, and
methodological differences among laboratories. Neverthe-
less, the phenomenon appears real, however defined, and 4
reports suggest that patients with aspirin resistance are at
increased risk for thrombotic complications.20,21,32,33 Ad-
ditionally, the concomitant administration of ibuprofen
seems to antagonize the irreversible platelet inhibition
induced by aspirin34 and may also be associated with
increased thrombotic complications.35,36
Clopidogrel offers added antiplatelet efficacy to aspirin in
patients with acute coronary syndromes3 or after stent im-
plantation.6 It is possible, however, that the clinical benefit of
clopidogrel is more complementary than additive. In the
CAPRIE study,2 clopidogrel reduced the annual absolute risk
of vascular death, myocardial infarction, and stroke by 0.5%
(5.3% versus 5.8%) compared with aspirin. In the CURE
trial,3 although the relative risk reduction for 30-day death or
myocardial infarction with aspirin/clopidogrel versus aspirin
alone was 21%, the absolute reduction was 1% (3.9%
versus 4.8%), an effect that easily could be accounted for by
clopidogrel efficacy in patients who were aspirin resistant or
taking concomitant ibuprofen with aspirin. If aspirin and
clopidogrel were proven to be complementary rather than
additive agents, the potential of limiting clopidogrel use to
patients who do not respond to aspirin would offer major
Figure 4. Percent platelet aggregation after clopidogrel, rifampin, and clopidogrel plus rifampin.
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cost-effectiveness advantages37 that would justify the cost of
measuring platelet function in patients receiving antiplatelet
therapy.
Subacute stent thrombosis continues to occur in 1% to 3%
of patients despite dual antiplatelet therapy.38,39 Future inves-
tigations need to determine whether these patients are aspirin
resistant, clopidogrel resistant, or both. Additionally, the
possibility that drug–drug interactions between aspirin and
ibuprofen34 or clopidogrel and atorvastatin14 contribute to
these events needs to be evaluated. In view of the recent
concern that the Cypher sirolimus-eluting coronary stent
(Cordis Corporation) may be associated with an increased
risk of subacute stent thrombosis, it should also be noted that
sirolimus promotes platelet aggregation.40 Therefore, the
efficacy of clopidogrel therapy in patients receiving these
stents needs to be defined.
Our study has several potential limitations. First, it could
be argued that measuring platelet aggregation is instrument
dependent and laboratory dependent. However, the same
interindividual variability was seen in this study with light
transmission aggregometry in platelet-rich plasma as with
point-of-care aggregometry in whole blood, and other inves-
tigators using the same instruments have produced similar
results.17,18,24 Second, one measure of platelet function may
not be sufficient to diagnose clopidogrel resistance. Never-
theless, resistance was defined by only 1 measurement in
each of the studies correlating aspirin resistance with in-
creased thrombotic complications.20,21,32,33 Third, the clinical
importance of low responders can be disputed. However, the
AU–Assessing Ultegra (GOLD) study41 suggested that sub-
optimal platelet function inhibition with a glycoprotein IIb/
IIIa antagonist, as measured by a point-of-care assay, was
associated with increased thrombotic complications after
percutaneous coronary intervention.
In conclusion, interindividual variations in platelet inhibi-
tion by both clopidogrel and aspirin exist, and some patients
are resistant to these antiplatelet agents because of biological
variability or drug–drug interactions. With clopidogrel, inter-
individual variation in platelet inhibition in part reflects
variation in CYP3A4 activity, and we have shown that this is
true even in healthy volunteers not treated with known
CYP3A4 inducers or inhibitors. Consistent definitions for
aspirin resistance and clopidogrel resistance are needed that
can be documented by reliable laboratory testing and associ-
ated with increased risk for thrombotic complications. In the
future, measurement of antiplatelet drug efficacy with a
point-of-care device and alternative antithrombotic strategies
for nonresponders or low responders could reduce the inci-
dence of thrombotic events that continue to occur despite oral
antiplatelet therapy.
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